Awakenings and awareness recovery in disorders of consciousness: Is there a role for drugs?

CNS Drugs

Volumn 24, Issue 8, 2010, Pages 625-638

  Pistoia, Francesca ^a,b   Mura, Elisa ^c   Govoni, Stefano ^c   Fini, Massimo ^d   Sarà, Marco ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Amantadine, therapeutic use; Amfetamine, therapeutic use; Amitriptyline, therapeutic use; Apomorphine, therapeutic use; Baclofen, therapeutic use; Coma; Consciousness disorders; Desipramine, therapeutic use; Lamotrigine, therapeutic use; Levodopa, therapeutic use; Methylphenidate, therapeutic use; Pramipexole, therapeutic use; Protriptyline, therapeutic use; Sertraline, therapeutic use; Zolpidem, therapeutic use

Indexed keywords

AMANTADINE; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; APOMORPHINE; BACLOFEN; BROMOCRIPTINE; DANTROLENE; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LAMOTRIGINE; LEVODOPA; METHYLPHENIDATE; NEUROTRANSMITTER; PRAMIPEXOLE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLPIDEM; CENTRAL DEPRESSANT AGENT; CENTRAL STIMULANT AGENT;

ACROMEGALY; AROUSAL; ATTENTION DEFICIT DISORDER; AWARENESS; BIPOLAR DISORDER; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM DEPRESSION; COGNITION; COGNITIVE DEFECT; COMA; CONSCIOUSNESS DISORDER; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; EPILEPSY; HEMISPHERE; HUMAN; HYPERPROLACTINEMIA; INFLUENZA; INSOMNIA; MINIMALLY CONSCIOUS STATE; NARCOLEPSY; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PARKINSON DISEASE; PERSISTENT VEGETATIVE STATE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; SLEEP WAKING CYCLE; SPASTICITY; THALAMUS NUCLEUS; WAKEFULNESS; CONSCIOUSNESS; CONSCIOUSNESS DISORDERS; DRUG EFFECTS; MEDLINE; METABOLISM;

CENTRAL NERVOUS SYSTEM DEPRESSANTS; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; COMA; CONSCIOUSNESS; CONSCIOUSNESS DISORDERS; HUMANS; MEDLINE; PERSISTENT VEGETATIVE STATE;

EID: 77954976662     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11535940-000000000-00000     Document Type: Review

References (66)

1. Plum F, Posner JB. The diagnosis of stupor and coma. Contemp Neurol Ser 1972; 10: 1-286
2. The Multi-Society Task Force on PVS. Medical aspects of the persistent vegetative state: first of two parts. N Engl J Med 1994; 330: 1499-1508
3. Giacino JT, Ashwal S, Childs N, et al. The minimally conscious state: definition and diagnostic criteria. Neurology 2002; 58: 349-353
4. Working Party of the Royal College of Physicians. The vegetative state: guidance on diagnosis and management. Clin Med 2003; 3: 249-254
5. Laureys S. The neural correlate of (un)awareness: lessons from the vegetative state. Trends Cogn Sci 2005; 9: 556-559
6. Laureys S, Faymonville ME, Luxen A, et al. Restoration of thalamocortical connectivity after recovery from persistent vegetative state. Lancet 2000; 355: 1790-1791
7. Lee L, Harrison LM, Mechelli A. A report of the functional connectivity workshop, Dusseldorf. Neuroimage 2003; 19: 457-465
8. Clauss RP, Guldenpfennig WM, Nel HW, et al. Extra-ordinary arousal from semi-comatose state on zolpidem: a case report. S Afr Med J 2000; 90: 68-72
9. Clauss R, Nel W. Drug induced arousal from the permanent vegetative state. NeuroRehabilitation 2006; 21: 23-28
10. Sara M, Sacco S, Cipolla F, et al. An unexpected recovery from permanent vegetative state. Brain Inj 2007; 21: 101-103
11. Sara M, Pistoia F, Mura E, et al. Intrathecal baclofen in patients with persistent vegetative state: two hypotheses. Arch Phys Med Rehabil 2009; 90: 1245-1249
12. Meythaler JM, Depalma L, Devivo MJ, et al. Sertraline to improve arousal and alertness in severe traumatic brain injury secondary to motor vehicle crashes. Brain Inj 2001; 15: 321-331
13. Schnakers C, Hustinx R, Vandewalle G, et al. Measuring the effect of amantadine in chronic anoxic minimally conscious state. J Neurol Neurosurg Psychiatry 2008; 79: 225-227
14. Liepert J. Pharmacotherapy in restorative neurology. Curr Opin Neurol 2008; 21: 639-643
15. De Marchi R, Bansal V, Hung A, et al. Review of awakening agents. Can J Neurol Sci 2005; 32: 4-17
16. Taira T, Hori T. Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl 2007; 97: 227-229
17. Showalter PE, Kimmel DN. Stimulating consciousness and cognition following severe brain injury: a new potential clinical use for lamotrigine. Brain Inj 2000; 14: 997-1001
18. Shames JL, Ring H. Transient reversal of anoxic brain in-jury related minimally conscious state after Zolpidem administration: a case report. Arch Phys Med Rehabil 2008; 89: 386-388
19. Cohen L, Chaaban B, Habert MO. Transient improvement of aphasia with zolpidem. N Engl J Med 2004; 350: 949-950
20. Singh R, McDonald C, Dawson K, et al. Zolpidem in a minimally conscious state. Brain Inj 2008; 22: 103-106
21. Whyte J, Myers R. Incidence of clinically significant re-sponses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil 2009; 88: 410-418
22. Lo YL, Tan EK, Ratnagopal P, et al. Zolpidem and its effects on hypoxic encephalopathy. Ann Neurol 2008; 64: 477-478
23. Horiguchi J, Inami Y, Shoda T. Effects of long-term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clin Neuropharmacol 1990; 13: 84-88
24. Nickels JL, Schneider WN, Dombovy ML, et al. Clinical use of amantadine in brain injury rehabilitation. Brain Inj 1994; 8: 709-718
25. Zafonte RD, Watanabe T, Mann NR. Amantadine: a po-tential treatment for the minimally conscious state. Brain Inj 1998; 12: 617-621
26. Meythaler JM, Brunner RC, Johnson A, et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 2002; 17: 300-313
27. McMahon MA, Vargus-Adams JN, Michaud LJ, et al. Ef-fects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study. Am J Phys Med Rehabil 2009; 88: 525-532
28. Reinhard DL, Whyte J, Sandel ME. Improved arousal and initiation following tricyclic antidepressant use in severe brain injury. Arch Phys Med Rehabil 1996; 77: 80-83
29. Fridman EA, Calvar J, Bonetto M, et al. Fast awakening from minimally conscious state with apomorphine. Brain Inj 2009; 23: 172-177
30. Fridman EA, Krimchansky BZ, Bonetto M, et al. Con-tinuous subcutaneous apomorphine for severe disorders of consciousness after traumatic brain injury. Brain Inj 2010; 24: 636-641
31. Passler MA, Riggs RV. Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromo-criptine. Arch Phys Med Rehabil 2001; 82: 311-315
32. Haig AJ, Ruess JM. Recovery from vegetative state of six months' duration associated with Sinemet (levodopa/carbidopa). Arch Phys Med Rehabil 1990 Dec; 71 (13): 1081-1083
33. Matsuda W, Matsumura A, Komatsu Y, et al. Awakenings from persistent vegetative state: report of three cases with parkinsonism and brain stem lesions on MRI. J Neurol Neurosurg Psychiatry 2003; 74: 1571-1573
34. Krimchansky BZ, Keren O, Sazbon L, et al. Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment. Brain Inj 2004; 18: 1099-1105
35. Matsuda W, Komatsu Y, Yanaka K, et al. Levodopa treatment for patients in persistent vegetative or minimally conscious states. Neuropsychol Rehabil 2005; 15: 414-427
36. Worzniak M, Fetters MD, Comfort M. Methylphenidate in the treatment of coma. J Fam Pract 1997; 44: 495-498
37. Moein H, Khalili HA, Keramatian K. Effect of methyl-phenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. Clin Neurol Neurosurg 2006; 108: 539-542
38. Whyte J, Hart T, Vaccaro M, et al. Effects of methylpheni-date on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil 2004; 83: 401-420
39. Patrick PD, Buck ML, Conaway MR, et al. The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj 2003; 17: 497-506
40. Wroblewski B, Glenn MB, Cornblatt R, et al. Protriptyline as an alternative stimulant medication in patients with brain injury: a series of case reports. Brain Inj 1993; 7: 353-362
41. Salva P, Costa J. Clinical pharmacokinetics and pharmaco-dynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995; 29: 142-153
42. Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 2004; 18 Suppl. 1: 9-15
43. Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002; 451: 103-110
44. Clauss RP. Neurotransmitters in coma, vegetative and minimally conscious states, pharmacological interventions. Med Hypotheses. Epub 2010 Mar 26 45.
45. Clauss R, Sathekge M, Nel W. Transient improvement of spinocerebellar ataxia with zolpidem. N Engl J Med 2004; 351: 511-512
46. Taira T. Intrathecal administration of GABA agonists in the vegetative state. Prog Brain Res 2009; 177: 317-328
47. Whyte J, Katz D, Long D, et al. Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: a multicenter study. Arch Phys Med Rehabil 2005; 86: 453-462
48. Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene: a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-373
49. Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997; 12 Suppl. 1: S2-9
50. Calabresi P, Centonze D, Cupini LM, et al. Ionotropic glu-tamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies. Neurobiol Dis 2003; 12: 82-88
51. Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003; 23: 484-495
52. Mysiw WJ, Jackson RD, Corrigan JD. Amitriptyline for post-traumatic agitation. Am J Phys Med Rehabil 1988; 67: 29-33
53. Jackson RD, Corrigan JD, Arnett JA. Amitriptyline for agitation in head injury. Arch Phys Med Rehabil 1985; 66: 180-181
54. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437: 1257-1263 (Pubitemid 41568665)
55. D'Aleo G, Saltuari L, Gerstenbrand F, et al. Sleep in the last remission stages of vegetative state of traumatic nature. Funct Neurol 1994; 9: 189-192
56. Isono M, Wakabayashi Y, Fujiki MM, et al. Sleep cycle in patients in a state of permanent unconsciousness. Brain Inj 2002; 16: 705-712
57. Huber R, Ghilardi MF, Massimini M, et al. Local sleep and learning. Nature 2004; 430: 78-81
58. Tononi G, Cirelli C. Sleep and synaptic homeostasis: a hypo-thesis. Brain Res Bull 2003; 62: 143-150
59. Lanni C, Govoni S, Lucchelli A, et al. Depression and anti-depressants: molecular and cellular aspects. Cell Mol Life Sci 2009; 66 (18): 2985-3008
60. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyski-nesia in Parkinson's disease. Cochrane Database Syst Rev 2003; (2): CD003467
61. Sawyer E, Mauro LS, Ohlinger MJ. Amantadine enhance-ment of arousal and cognition after traumatic brain injury. Ann Pharmacother 2008; 42: 247-252
62. Rogoz Z, Skuza G, Legutko B. Repeated co-treatment with fluoxetine and amantadine induces brain-derived neuro-trophic factor gene expression in rats. Pharmacol Rep 2008; 60: 817-826
63. Liepert J. Pharmacotherapy in restorative neurology. Curr Opin Neurol 2008; 21: 639-643
64. Walker-Batson D, Smith P, Curtis S, et al. Amphetamine paired with physical therapy accelerates motor recovery after stroke: further evidence. Stroke 1995; 26: 2254-2259
65. Sara M, Pistoia F. Defining consciousness: lessons from patients and modern techniques. J Neurotrauma 2010 Apr; 27 (4): 771-773
66. Whyte J. Treatments to enhance recovery from the vegeta-tive and minimally conscious states: ethical issues surrounding efficacy studies. Am J Phys Med Rehabil 2007; 86: 86-92